<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The war against <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> has seen a proliferation in armamentarium over the last decades </plain></SENT>
<SENT sid="1" pm="."><plain>A new <z:chebi fb="0" ids="35610">antineoplastic</z:chebi> agent, trastuzumab, was synthesized in 1991 and gained United States Food and Drug Administration approval in 1998 for treatment of metastatic <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Cardiotoxicity manifesting as <z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo> is a rarely reported adverse effect of trastuzumab </plain></SENT>
<SENT sid="3" pm="."><plain>We hereby report a case of <z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo>, which occurred following trastuzumab chemotherapy in a 32-year-old female </plain></SENT>
<SENT sid="4" pm="."><plain>The patient responded to discontinuation of trastuzumab and standard medical treatment </plain></SENT>
<SENT sid="5" pm="."><plain>Extensive search of Indian literature revealed no reported case of <z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo> occurring due to trastuzumab </plain></SENT>
</text></document>